Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes

Young Ae Kang, Tae Sun Shim, Won Jung Koh, Seung Heon Lee, Chang Hoon Lee, Jae Chol Choi, Jae Ho Lee, Seung Hun Jang, Kwang Ha Yoo, Ki Hwan Jung, Ki Uk Kim, Sang Bong Choi, Yon Ju Ryu, Kyung Chan Kim, Soojung Um, Yong Soo Kwon, Yee Hyung Kim, Won Il Choi, Kyeongman Jeon, Yong Il HwangSe Joong Kim, Hyun Kyung Lee, Eunyoung Heo, Jae Joon Yim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB.

Original languageEnglish
Pages (from-to)364-370
Number of pages7
JournalAnnals of the American Thoracic Society
Volume13
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Multidrug-Resistant Tuberculosis
Levofloxacin
Fluoroquinolones
Therapeutics
moxifloxacin

Keywords

  • Fluoroquinolones
  • Levofloxacin
  • Moxifloxacin
  • Multidrug-resistant tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. / Kang, Young Ae; Shim, Tae Sun; Koh, Won Jung; Lee, Seung Heon; Lee, Chang Hoon; Choi, Jae Chol; Lee, Jae Ho; Jang, Seung Hun; Yoo, Kwang Ha; Jung, Ki Hwan; Kim, Ki Uk; Choi, Sang Bong; Ryu, Yon Ju; Kim, Kyung Chan; Um, Soojung; Kwon, Yong Soo; Kim, Yee Hyung; Choi, Won Il; Jeon, Kyeongman; Hwang, Yong Il; Kim, Se Joong; Lee, Hyun Kyung; Heo, Eunyoung; Yim, Jae Joon.

In: Annals of the American Thoracic Society, Vol. 13, No. 3, 01.03.2016, p. 364-370.

Research output: Contribution to journalArticle

Kang, YA, Shim, TS, Koh, WJ, Lee, SH, Lee, CH, Choi, JC, Lee, JH, Jang, SH, Yoo, KH, Jung, KH, Kim, KU, Choi, SB, Ryu, YJ, Kim, KC, Um, S, Kwon, YS, Kim, YH, Choi, WI, Jeon, K, Hwang, YI, Kim, SJ, Lee, HK, Heo, E & Yim, JJ 2016, 'Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes', Annals of the American Thoracic Society, vol. 13, no. 3, pp. 364-370. https://doi.org/10.1513/AnnalsATS.201510-690BC
Kang, Young Ae ; Shim, Tae Sun ; Koh, Won Jung ; Lee, Seung Heon ; Lee, Chang Hoon ; Choi, Jae Chol ; Lee, Jae Ho ; Jang, Seung Hun ; Yoo, Kwang Ha ; Jung, Ki Hwan ; Kim, Ki Uk ; Choi, Sang Bong ; Ryu, Yon Ju ; Kim, Kyung Chan ; Um, Soojung ; Kwon, Yong Soo ; Kim, Yee Hyung ; Choi, Won Il ; Jeon, Kyeongman ; Hwang, Yong Il ; Kim, Se Joong ; Lee, Hyun Kyung ; Heo, Eunyoung ; Yim, Jae Joon. / Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. In: Annals of the American Thoracic Society. 2016 ; Vol. 13, No. 3. pp. 364-370.
@article{aaae47c05d0c4670b692e2e6101f2b02,
title = "Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes",
abstract = "Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1{\%}) in the levofloxacin group and 54 (73.0{\%}) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1{\%}, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4{\%}, P = 0.54) and treatment success rates (84.4 vs. 79.7{\%}, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5{\%}, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9{\%}, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB.",
keywords = "Fluoroquinolones, Levofloxacin, Moxifloxacin, Multidrug-resistant tuberculosis",
author = "Kang, {Young Ae} and Shim, {Tae Sun} and Koh, {Won Jung} and Lee, {Seung Heon} and Lee, {Chang Hoon} and Choi, {Jae Chol} and Lee, {Jae Ho} and Jang, {Seung Hun} and Yoo, {Kwang Ha} and Jung, {Ki Hwan} and Kim, {Ki Uk} and Choi, {Sang Bong} and Ryu, {Yon Ju} and Kim, {Kyung Chan} and Soojung Um and Kwon, {Yong Soo} and Kim, {Yee Hyung} and Choi, {Won Il} and Kyeongman Jeon and Hwang, {Yong Il} and Kim, {Se Joong} and Lee, {Hyun Kyung} and Eunyoung Heo and Yim, {Jae Joon}",
year = "2016",
month = "3",
day = "1",
doi = "10.1513/AnnalsATS.201510-690BC",
language = "English",
volume = "13",
pages = "364--370",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes

AU - Kang, Young Ae

AU - Shim, Tae Sun

AU - Koh, Won Jung

AU - Lee, Seung Heon

AU - Lee, Chang Hoon

AU - Choi, Jae Chol

AU - Lee, Jae Ho

AU - Jang, Seung Hun

AU - Yoo, Kwang Ha

AU - Jung, Ki Hwan

AU - Kim, Ki Uk

AU - Choi, Sang Bong

AU - Ryu, Yon Ju

AU - Kim, Kyung Chan

AU - Um, Soojung

AU - Kwon, Yong Soo

AU - Kim, Yee Hyung

AU - Choi, Won Il

AU - Jeon, Kyeongman

AU - Hwang, Yong Il

AU - Kim, Se Joong

AU - Lee, Hyun Kyung

AU - Heo, Eunyoung

AU - Yim, Jae Joon

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB.

AB - Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB.

KW - Fluoroquinolones

KW - Levofloxacin

KW - Moxifloxacin

KW - Multidrug-resistant tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84989153983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989153983&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201510-690BC

DO - 10.1513/AnnalsATS.201510-690BC

M3 - Article

C2 - 26871879

AN - SCOPUS:84989153983

VL - 13

SP - 364

EP - 370

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 3

ER -